Year: 2026
Type: article
Abstract: Background: Pterygium is a common fibrovascular conjunctival lesion in tropical countries such as Bangladesh, and bleeding from its vascular bed can obscure the surgical field. Brimonidine tartrate, a selective α2-adrenergic agonist used to lower intraocular pressure (IOP), also causes conjunctival vasoconstriction and is applied during surgery for hemostasis, but its effect on IOP after pterygium excision is unclear. Objective: To evaluate the change in IOP following peroperative use of brimonidine in pterygium surgery. Methodology: This comparative observational study was conducted in the Cornea Department of Ispahani Islamia Eye Institute and Hospital, Dhaka, on 70 eyes of 70 consecutive patients undergoing pterygium excision. Brimonidine 0.2%-soaked applicators were used for hemostasis in 45 eyes; 25 eyes received conventional hemostasis. IOP was measured by non-contact tonometry preoperatively and on the first or second postoperative day and analyzed with IBM SPSS Statistics version 27 using paired and Welch t tests. Results: The mean age was 48.3±13.3 years and 42 (60.0%) patients were male. Overall IOP changed from 13.1±2.9 to 12.8±2.9 mmHg (mean change −0.27 mmHg, 95% CI −0.93 to 0.39; p=0.41). The mean change was +0.04 mmHg with brimonidine (p=0.92) and −0.84 mmHg without it (p=0.11); the between-group difference was not significant (p=0.19). Postoperative IOP ≥21 mmHg and a rise ≥6 mmHg each occurred in 3 (4.3%) eyes. Conclusion: Peroperative brimonidine used for hemostasis in pterygium surgery neither significantly lowered nor raised early postoperative IOP and appears safe in non-glaucomatous eyes. J. Natl.Inst.Ophthalmol.2025;8(2): 34-39
Institution: Ispahani Islamia Eye Institute and Hospital
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7236725076
